MoonLake Immunotherapeutics

MLTX

Market cap $939M

New York, New York--(Newsfile Corp. - December 1, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Lead Partner Reed Kathrein Investigating Alleged Undisclosed Truth: Did SLK's Nanobody Structure Truly Confer a Superior Clinical Benefit Over Monoclonal Antibodies? SAN FRANCISCO , Dec. 1, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) is December 15, 2025.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 1, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the "Company") (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

New York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

For the quarter, Voya MidCap Opportunities Strategy Fund outperformed the Index on a NAV basis due largely to favorable stock selection. Key contributors to performance included Kratos Defense & Security Solutions, Inc. (KTOS), Comfort Systems USA, Inc. (FIX), and AppLovin Corp (APP). Key detractors from performance included MoonLake Immunotherapeutics (MLTX), Tradeweb Markets, Inc. (TW), and Verisk Analytics, Inc. (VRSK).

LOS ANGELES , Dec. 1, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX). IF YOU SUFFERED A LOSS ON YOUR MOONLAKE INVESTMENTS, CLICK HERE BEFORE DECEMBER 15, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) between March 10 , 202 4 and September 29 , 202 5, inclusive. Should You Join This Class Action Lawsuit?

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

PHILADELPHIA , Dec. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm  Berger Montague PC  announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of  March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025 , seek to be appointed as a lead plaintiff representative of the class.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.